AIIMS is working with ICMR on the same
The All India Institute of Medical Sciences (AIIMS) is planning to conduct a clinical trial of the convalescent plasma therapy in the treatment of COVID-19 and modalities of taking approvals from the Drug Controller General (India) are being worked out.
AIIMS Director Dr Randeep Guleria said the mode of treatment in COVID-19 is still at an ‘experimental stage’ and there is a need for good and well conducted research trials before its benefit and this mode of therapy can be recommended for routine use in coronavirus patients.
“AIIMS is working with the ICMR to conduct a clinical trial on the efficacy of convalescent plasma therapy in COVID-19 patients,” he said.
The doctor said it is necessary for all institutes to take necessary approvals from the Indian Council of Medical Research (ICMR) and the Drug Controller General (India) and follow proper clinical practice guidelines for this research.
“In very limited studies, globally, convalescent plasma as an adjunct to other supportive therapies and treatments has shown some benefit in the management of severe patients of COVID-19,” Guleria said.
He also underlined that plasma has to be tested for its safety and it should have sufficient antibodies to be useful for giving it to COVID-19 patients.
“Giving plasma from a recovered patient without testing whether it has enough antibody titer or not may cause more harm than good as it can cause transfusion-related reactions,” he said.
Dr Neeraj Nischal, Associate Professor in the department of medicine at AIIMS, said that in the absence of any specific antiviral medications for the treatment of COVID-19, convalescent plasma (plasma from patients who have recovered from the illness) is being seen as a promising therapeutic option.
But for plasma therapy to be effective, plasma must contain a sufficient amount of neutralising antibody against that infection.
“This therapy is not foolproof and is associated with risks like inadvertent transfer of blood-borne infections and reactions to serum constituents, including immunological reactions such as serum sickness, and may worsen the clinical condition,” Dr Nischal said.
Plasma constitutes about 55 per cent of the total blood component and has high concentration of neutralising antibodies. When transfused, it acts as a passive immunisation and provides immediate immunity to susceptible or infected persons by neutralising the virus or by dampening the cytokine storm, he said.